The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Antsiferov M.B.

Éndokrinologicheskiĭ dispanser Departamenta zdravookhraneniia Moskvy

Galstian G.R.

FGBU "Éndokrinologicheskiĭ nauchnyĭ tsentr", Moskva

Zilov A.V.

Kafedra éndokrinologii Pervogo MGMU im. I.M. Sechenova, Moskva

Mayorov A.Y.

Endocrinology Research Centre, Moscow, Russian Federation

Markova T.N.

Kafedra vnutrennikh bolezneĭ Chuvashskogo gosudarstvennogo universiteta, Cheboksary

Demidov N.A.

Troitsky and Novomoskovsky Administrative District, Moscow, Russia

Koteshkova Olga M.

Moscow Health Care Department, Endocrinology Dispanserium, Moscow, Russia

Laptev D.N.

Endocrinology Research Centre, Moscow, Russian Federation

Vitebskaia A.V.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Alekseeva Y.G.

Novo Nordisk, Moscow, Russia

Stavtseva S.I.

Novo Nordisk, Moscow, Russia

Resolution on the results of the first working meeting of the Scientific Advisory Board «Actual problems of glycemic variability as a new criterion of glycemic control and safety of diabetes therapy»

Authors:

Antsiferov M.B., Galstian G.R., Zilov A.V., Mayorov A.Y., Markova T.N., Demidov N.A., Koteshkova Olga M., Laptev D.N., Vitebskaia A.V., Alekseeva Y.G., Stavtseva S.I.

More about the authors

Journal: Problems of Endocrinology. 2019;65(3): 204‑211

DOI: 10.14341/probl10197

Read: 1385 times

Download PDF (RU)
Contact the author
Table of contents

RESOLUTION ON THE RESULTS OF THE FIRST WORKING MEETING OF THE SCIENTIFIC ADVISORY BOARD «ACTUAL PROBLEMS OF GLYCEMIC VARIABILITY AS A NEW CRITERION OF GLYCEMIC CONTROL AND SAFETY OF DIABETES THERAPY»
RESOLUTION ON THE RESULTS OF THE FIRST WORKING MEETING OF THE SCIENTIFIC ADVISORY BOARD «ACTUAL PROBLEMS OF GLYCEMIC VARIABILITY AS A NEW CRITERION OF GLYCEMIC CONTROL AND SAFETY OF DIABETES THERAPY»

To cite this article:

Antsiferov MB, Galstian GR, Zilov AV, et al. . Resolution on the results of the first working meeting of the Scientific Advisory Board «Actual problems of glycemic variability as a new criterion of glycemic control and safety of diabetes therapy». Problems of Endocrinology. 2019;65(3):204‑211. (In Russ.)
https://doi.org/10.14341/probl10197

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The role of quantitative body composition analysis in popu­lation in the asse­ssment and moni­toring of cardiovascular risk meta­bolic factors. Russian Journal of Preventive Medi­cine. 2024;(12):128-134
Restoration of spermatogenesis suppressed by the use of testosterone, antiestrogen therapy in men with type 2 diabetes mellitus. Russian Journal of Human Reproduction. 2024;(6):156-160
Diabetic reti­nopathy and pregnancy. Russian Annals of Ophthalmology. 2024;(6):145-151
Psoriasis: analysis of como­rbid pathology. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(1):16-21
Cognitive functions asse­ssment of elde­rly patients with type 2 diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):46-50
Features of comprehensive treatment in a patient with complicated type 2 diabetes mellitus: A clinical case. Piro­gov Russian Journal of Surgery. 2025;(6):128-132
Early diagnosis and effe­ctive therapy of diabetic poly­neuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):62-68
Hype­rtensive diso­rders of pregnancy as a risk factor for chro­nic non-communicable diseases. Russian Journal of Preventive Medi­cine. 2025;(6):114-119
Cere­brovascular disease in clinical practice. Reso­lution of the Expert Council of the Russian Scientific Medi­cal Society of Therapists. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):105-111
Late complications and quality of life after multivisceral surgeries with pancreatoduodenectomy. Piro­gov Russian Journal of Surgery. 2025;(7):36-45
Abstract:

June 19, 2018 the meeting of the Scientific Advisory Board took place in Moscow, chaired by Professor G.R. Galstyan, (co-chair – A.V. Zilov) devoted to the discussion of the possibilities of improving the results of treatment of diabetes mellitus (DM) by consideration of «variability of glycemia» (VG) as an additional criterion of the glycemic control effectiveness (especially of insulin therapy) as well as one of the goals of treatment in patients with unstable glycemia. The purpose of the working meeting was to develop a strategy for the introduction of VG as a predictor and an additional criterion in assessing the effectiveness and safety of hypoglycemic therapy to improve the pharmacotherapy of diabetes and reduce cardiovascular and total mortality. Aims: – to conduct a comprehensive data analysis of the relationship between VG and adverse DM outcomes, such as hypoglycemia, micro-and macrovascular complications, cardiovascular and total mortality; – to accumulate and analyze published data and the experience of decrease of VG and improving outcomes of diabetes on the background of different versions of insulin therapy; – to compare existing methods of glycaemia monitoring and VG assessment, their validity and availability in real practice in the context of limited budget; – to analyze the informativeness, clinical and prognostic significance of various parameters of VG assessment and determine their reasonable «minimum» for a comprehensive assessment of VG as a criterion for evaluating the effectiveness of treatment of DM and predictors of negative diabetes outcomes. The following reports were heard during the discussion: Glycemic variability: clinical and prognostic value. Types of glycemic variability. (Alexey V. Zilov, MD, PhD in Medicine, Assistant Professor). Methods of assessment of variability of glycemia in clinical trials and routine practice (Tatiana N. Markova, MD, PhD in Medicine, Professor). Current international and national recommendations on glycemic monitoring (Gagik R. Galstyan, MD, PhD in Medicine, Professor). Peculiarities of glycemic variability and its evaluation among children and adolescents (Alisa V. Vitebskaya, MD, PhD in Medicine).

Keywords:

glycemia variability
fasting plasma glucose
postprandial glycemia
HbA1c
coefficient of variability
continuous glucose monitoring
self-measured blood glucose
diabetes mellitus

Authors:

Antsiferov M.B.

Éndokrinologicheskiĭ dispanser Departamenta zdravookhraneniia Moskvy

Galstian G.R.

FGBU "Éndokrinologicheskiĭ nauchnyĭ tsentr", Moskva

Zilov A.V.

Kafedra éndokrinologii Pervogo MGMU im. I.M. Sechenova, Moskva

Mayorov A.Y.

Endocrinology Research Centre, Moscow, Russian Federation

Markova T.N.

Kafedra vnutrennikh bolezneĭ Chuvashskogo gosudarstvennogo universiteta, Cheboksary

Demidov N.A.

Troitsky and Novomoskovsky Administrative District, Moscow, Russia

Koteshkova Olga M.

Moscow Health Care Department, Endocrinology Dispanserium, Moscow, Russia

Laptev D.N.

Endocrinology Research Centre, Moscow, Russian Federation

Vitebskaia A.V.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Alekseeva Y.G.

Novo Nordisk, Moscow, Russia

Stavtseva S.I.

Novo Nordisk, Moscow, Russia

Close metadata

References:

  1. Nalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab. 2010;12(4):288–298. https://doi.org/10.1111/j.1463-1326.2009.01160.x.
  2. Hirakawa Y, Arima H, Zoungas S, et al. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care. 2014;37(8):2359–2365. https://doi.org/10.2337/dc14-0199.
  3. Hirsch IB. Glycemic variability and diabetes complications: does it matter? Of course it does! Diabetes Care. 2015;38(8):1610–1614. https://doi.org/10.2337/dc14-2898.
  4. Wentholt IM, Kulik W, Michels RP, et al. Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia. 2008;51(1):183–190. https://doi.org/10.1007/s00125-007-0842-6.
  5. Siegelaar SE, Barwari T, Kulik W, et al. No relevant relationship between glucose variability and oxidative stress in well-regulated type 2 diabetes patients. J Diabetes Sci Tech. 2011;5(1):86–92. https://doi.org/10.1177/193229681100500112.
  6. Ohara M, Fukui T, Ouchi M, et al. Relationship between daily and day-to-day glycemic variability and increased oxidative stress in type 2 diabetes. Diabetes Res Clin Pract. 2016;122:62–70. https://doi.org/10.1016/j.diabres.2016.09.025.
  7. Kohnert KD, Augstein P, Zander E, et al. Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care. 2009;32(6):1058–1062. https://doi.org/10.2337/dc08-1956.
  8. Kohnert KD, Freyse EJ, Salzsieder E. Glycaemic variability and pancreatic b-cell dysfunction. Curr Diabetes Rev. 2013;8(5):345–354. https://doi.org/10.2174/157339912802083513.
  9. Kim MK, Jung HS, Yoon CS, et al. The effect of glucose fluctuation on apoptosis and function of INS-1 pancreatic beta cells. Korean Diabetes J. 2010;34(1):47–54. https://doi.org/10.4093/kdj.2010.34.1.47.
  10. Zhang X, Xu X, Jiao X, et al. The effects of glucose fluctuation on the severity of coronary artery disease in type 2 diabetes mellitus. J Diabetes Res. 2013;2013:576916. https://doi.org/10.1155/2013/576916.
  11. Muggeo M, Zoppini G, Bonora E, et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care. 2000;23(1):45–50. https://doi.org/10.2337/diacare.23.1.45.
  12. Lin CC, Li CI, Yang SY, et al. Variation of fasting plasma glucose: a predictor of mortality in patients with type 2 diabetes. Am J Med. 2012;125(4):416.e9-18. https://doi.org/10.1016/j.amjmed.2011.07.027.
  13. Zinman B, Marso SP, Poulter NR, et al. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia. 2018;61(1):48–57. https://doi.org/10.1007/s00125-017-4423-z
  14. Krinsley JS. Glycemic variability: a strong independent predictor of mortality in critically ill patients. Crit Care Med. 2008;36(11):3008–3013. https://doi.org/10.1097/CCM.0b013e31818b38d2
  15. DeVries JH. Glucose variability: where it is important and how to measure it. Diabetes. 2013;62(5):1405–1408. https://doi.org/10.2337/db12-1610
  16. Klimontov VV, Myakina NE. Glycaemic variability in diabetes: a tool for assessing the quality of glycaemic control and the risk of complications. Diabetes mellitus. 2014;17(2):76–82. (In Russ) https://doi.org/10.14341/dm2014276-82
  17. Bergenstal RM. Glycemic variability and diabetes complications: does it matter? Simply put, there are better glycemic markers! Diabetes Care. 2015;38(8):1615–1621. https://doi.org/10.2337/dc15-0099
  18. Monnier L, Colette C, Wojtusciszyn A, et al. Toward defining the threshold between low and high glucose variability in diabetes. Diabetes Care. 2017;40(7):832–838. https://doi.org/10.2337/dc16-1769
  19. Kovatchev BP, Cox DJ, Farhy LS, et al. Episodes of severe hypoglycemia in type 1 diabetes are preceded and followed within 48 hours by measurable disturbances in blood glucose. J Clin Endocrinol Metab. 2000;85(11):4287–4292. https://doi.org/10.1210/jcem.85.11.6999
  20. Patton SR, Clements MA. Average daily risk range as a measure for clinical research and routine care. J Diabetes Sci Technol. 2013;7(5):1370–1375. https://doi.org/10.1177/193229681300700529
  21. Ryan EA, Shandro T, Green K, et al. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes. 2004;53(4):955–962. https://doi.org/10.2337/diabetes.53.4.955
  22. Siegelaar SE, Holleman F, Hoekstra JB, DeVries JH. Glucose variability: does it matter. Endocr Rev. 2010;31(2):171–182. https://doi.org/10.1210/er.2009-0021.
  23. Qu Y, Jacober SJ, Zhang Q, et al. Rate of hypoglycemia in insulin-treated patients with type 2 diabetes can be predicted from glycemic variability data. Diabetes Technol Ther. 2012;14(11):1008–1012. https://doi.org/10.1089/dia.2012.0099
  24. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295(14):1681–1687. https://doi.org/10.1089/dia.2012.0099
  25. Seok H, Huh JH, Kim HM, et al. 1,5-anhydroglucitol as a useful marker for assessing short-term glycemic excursions in type 1 diabetes. Diabetes Metab J. 2015;39(2):164–170. https://doi.org/10.4093/dmj.2015.39.2.164
  26. Bailey TS, Bhargava A, DeVries JH, et al. Day-to-day variability of fasting self-measured plasma glucose (SMPG) correlates with risk of hypoglycemia in adults with type 1 (T1D) or type 2 diabetes (T2D). Diabetes. 2017;66(Suppl 1):A104-105(394-P). https://doi.org/10.2337/db17-381-663
  27. Bailey TS, Bhargava A, DeVries JH, et al. Within-day variability based on 9-point profiles correlates with risk of overall and nocturnal hypoglycemia in adults with type 1 (t1d) and type 2 diabetes (T2D). Diabetes. 2017;66(Suppl 1):A107(404-P). https://doi.org/10.2337/db17-381-663
  28. Vora J, Heise T. Variability of glucose‐lowering effect as a limiting factor in optimizing basal insulin therapy: a review. Diabetes Obes Metab. 2013;15(8):701–712. https://doi.org/10.1111/dom.12087
  29. Heise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower pharmacodynamics variability than insulin glargine under steadystate conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14(9):859–864. https://doi.org/10.1111/j.1463-1326.2012.01627.x
  30. Heise T, Nørskov M, Nosek L, et al. Insulin degludec: lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. Diabetes Obes Metab. 2017;19(7):1032–1039. https://doi.org/10.1111/dom.12938
  31. Iga R, Uchino H, Kanazawa K, et al. Glycemic variability in type 1 diabetes compared with degludec and glargine on the morning injection: an open-label randomized controlled trial. Diabetes Ther. 2017;8(4):783–792. https://doi.org/10.1007/s13300-017-0269-0
  32. Takahashi H, Nishimura R, Onda Y, et al. Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin detemir using continuous glucose monitoring: a randomized, cross-over, pilot study. Expert Opin Pharmacother. 2017;18(4):335–342. https://doi.org/10.1080/14656566.2017.1293652
  33. Henao-Carrilloa DC, Muñoza OM, Gómeza AM, et al. Reduction of glycemic variability with degludec insulin in patients with unstable diabetes. J Clin Transl Endocrinol. 2018;12:8–12. https://doi.org/10.1016/j.jcte.2018.03.003
  34. Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377(8):723–732. https://doi.org/10.1056/NEJMoa1615692
  35. Danne T, Nimri R, Battelino T, et al. International Consensus on use of continuous glucose monitoring. Diabetes Care. 2017; 40(12):1631–1640. https://doi.org/10.2337/dc17-1600
  36. Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). Diabetes Technol Ther. 2013;15(3):198–211. https://doi.org/10.1089/dia.2013.0051.
  37. Su G, Mi S, Tao H, et al. Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol. 2011;10:19. https://doi.org/10.1186/1475-2840-10-19.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.